Filter articles using the following links

GenSight Biologics Reports Full Year 2022 Consolidated Financial Results

GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial

GenSight Biologics to Present at Upcoming Medical Conferences

GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines

GenSight Biologics Announces its 2023 Financial Calendar

Rare Disease Day 2023: GenSight Biologics Raises Awareness of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Announces 1 Year Safety data and Efficacy signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa

GenSight Biologics announces the drawdown of the first EUR 8 million tranche under its credit agreement with the European Investment Bank